MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c)

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrial-derived peptide consisting of 16 amino acids.
It was first described in 2015 and is unique because it is encoded within mitochondrial DNA rather than nuclear DNA.
Research suggests MOTS-c plays an important role in regulating metabolism, insulin sensitivity, exercise capacity, and cellular stress responses.
It remains experimental and is not FDA-approved for therapeutic use.

How It Is Used in Research Settings

• Explored in metabolic research for improving insulin sensitivity and glucose regulation.
• Studied in models of obesity and type 2 diabetes for its role in reducing weight gain and improving metabolic flexibility.
• Investigated for enhancing exercise performance and endurance via mitochondrial biogenesis and AMPK activation.
• Examined in aging research for potential roles in longevity, stress resistance, and skeletal muscle health.

Proposed Uses (Research Areas)

• Metabolic disorders such as obesity, insulin resistance, and type 2 diabetes.
• Exercise physiology and performance enhancement studies.
• Aging and longevity models — potential anti-aging peptide through mitochondrial regulation.
• Cellular stress response and antioxidant defense research.

How It Is Dosed in Research Settings

• Injectable: Commonly studied at 5–15 mg subcutaneous injection, administered 2–3 times weekly in research protocols.
• Alternative dosing: Some studies evaluate daily dosing at lower levels (e.g., 2–5 mg/day) for metabolic impact.
• Cycle length: Research trials often range from 4–12 weeks depending on metabolic or performance outcomes being investigated.
• Handling: Reconstituted with bacteriostatic water, refrigerated storage recommended.

Important Considerations

• Regulatory status: MOTS-c is not FDA-approved; all current use is experimental and limited to research contexts.
• Evidence base: Most data comes from preclinical studies (rodents, cell models). Human research is very limited but emerging.
• Safety: Short-term animal studies suggest low toxicity; long-term safety in humans is not known. Purity and sourcing are critical concerns.

Disclaimer

This material is provided for educational purposes only and summarizes published research on MOTS-c.
It is not medical advice. MOTS-c is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.

This peptide is for research use only.